EKG Screening for Psychiatric Medications

Risk-Stratified Approach to EKG Screening

The European Heart Journal recommends that EKG screening is not universally required when starting psychiatric medications, but should be obtained for patients with cardiac risk factors or when prescribing medications with known QT-prolonging effects (Class B/B* drugs) 1
Patients without cardiac risk factors starting low-risk psychiatric medications can begin treatment without baseline EKG, according to the European Heart Journal guidelines 1, 2
Low-risk agents include most SSRIs, SNRIs, and benzodiazepines, which have minimal pro-arrhythmic potential, as stated by the European Heart Journal 1, 3

Obtain baseline EKG before starting psychiatric medications if the patient has a history of cardiac disease (ischemic heart disease, heart failure, structural heart disease, congenital heart disease), as recommended by the European Heart Journal 3
Baseline EKG is also recommended for patients with cardiac symptoms: chest pain, dyspnea, palpitations, syncope or near-syncope, according to the European Heart Journal 6
Family history of sudden cardiac death or inherited arrhythmia syndromes (long QT syndrome, Brugada syndrome) is also a risk factor that requires baseline EKG, as stated by the European Heart Journal 2

The European Heart Journal guidelines recommend always obtaining baseline EKG when prescribing tricyclic antidepressants, due to their significant QT prolongation risk 7, 8
Phenothiazines (e.g., thioridazine) also require baseline EKG, as they can cause QT prolongation, according to the European Heart Journal guidelines 7, 8
Methadone maintenance programs require baseline EKG for all patients with risk factors, annually, and when daily dose exceeds 100-120 mg, as recommended by the European Heart Journal 3

For patients on Class B/B* medications, repeat EKG within 1-2 weeks after starting medication, as recommended by the European Heart Journal 1
Repeat EKG after any significant dose increase, according to the European Heart Journal guidelines 8

The European Heart Journal guidelines provide the most comprehensive risk-stratified approach, emphasizing that psychiatric patients have higher baseline cardiovascular disease prevalence due to lifestyle factors, poor treatment compliance, and possible shared genetic factors 1, 4
The ACC/AHA guidelines classify EKG monitoring for psychotropic agents as Class I indication when prescribed therapy may produce adverse effects detectable by EKG changes, supporting selective rather than universal screening 9, 7, 8

Don't skip baseline EKG in elderly patients (>50 years), even for "low-risk" medications, as this population has 10-fold higher sudden cardiac death rates, according to the European Heart Journal guidelines 4, 6, 5
Don't assume all antipsychotics carry equal risk, as they vary significantly in QT-prolonging effects, and don't forget to assess concurrent medications for drug interactions and additive QT prolongation, as recommended by the European Heart Journal 1, 2